Nov 5, 4:07 PM ET
Artivion reported third-quarter 2026 revenue of $123.8 million, up 9% from $113.4 million a year earlier, but swung to a GAAP net loss of $7.9 million, or $0.16 per diluted share, from net income of $6.5 million, or $0.13 per diluted share, in the prior-year quarter. Adjusted EBITDA fell 8% to $22.5 million, and the company narrowed its full-year 2026 revenue and adjusted EBITDA guidance ranges.
- Q3 2026 revenue of $123.8 million, up 9% on both GAAP and constant currency bases; On-X grew 13% in constant currency.
- Q3 2026 GAAP net loss of $(7.9) million, or $(0.16) per diluted share, versus net income of $6.5 million, or $0.13, in Q3 2025.
- Adjusted EBITDA declined 8% to $22.5 million from $24.6 million.
- FY 2026 revenue guidance narrowed to $484 million to $492 million from $480 million to $496 million; adjusted EBITDA guidance narrowed to $93 million to $98 million from $92 million to $99 million.
Read the filing on SEC.gov ↗
Aug 6, 4:08 PM ET
Artivion reported second-quarter 2026 revenue of $125.8 million, up 11% from a year earlier, and adjusted EBITDA of $26.4 million, up 7%. The company posted a GAAP net loss of $13.5 million ($0.28 per diluted share), compared with net income of $1.3 million a year earlier, and reiterated its full-year 2026 revenue and adjusted EBITDA guidance. For shareholders, revenue grew while GAAP profit fell, and the filing also reports the completed Endospan acquisition and an FDA approval for the AMDS Hybrid Prosthesis.
- Q2 2026 revenue was $125.8 million, up 11% on a GAAP basis and 9% in constant currency versus Q2 2025 ($113.0 million).
- Q2 2026 GAAP net loss was $13.5 million ($0.28 per diluted share), versus net income of $1.3 million ($0.03) in Q2 2025; non-GAAP net income was $6.3 million ($0.13 per share), down from $10.7 million ($0.24).
- Full-year 2026 guidance was reiterated: revenue of $480 million to $496 million and adjusted EBITDA of $92 million to $99 million.
- The company completed its acquisition of Endospan Ltd. in May 2026 and announced U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.
Read the filing on SEC.gov ↗
May 7, 4:10 PM ET
Artivion reported first-quarter 2026 revenue of $116.3 million, up 18% on a GAAP basis from a year earlier, and net income of $1.4 million, or $0.03 per diluted share, compared with a net loss of $0.5 million a year earlier. The company lowered its full-year 2026 revenue and adjusted EBITDA guidance and said it has exercised its option to acquire Endospan, with an expected net purchase price of about $135.0 million to be funded by term loan borrowings and expected to close in the second quarter of 2026.
- Q1 2026 revenue $116.3 million, up 18% GAAP and 12% constant currency; net income $1.4 million, or $0.03 per diluted share
- 2026 revenue guidance cut to $480 million to $496 million from $486 million to $504 million
- 2026 adjusted EBITDA guidance cut to $100 million to $107 million from $105 million to $110 million
- Endospan option exercised May 7, 2026; base price $175.0 million, expected net price about $135.0 million, plus up to $200.0 million contingent consideration
Read the filing on SEC.gov ↗
Feb 12, 4:10 PM ET
Artivion reported fourth-quarter 2025 revenue of $116.0 million, up from $97.3 million a year earlier, and GAAP net income of $2.4 million, or $0.05 per diluted share, compared with a net loss of $16.5 million in the prior-year quarter. The company also guided to 2026 revenue of $486 million to $504 million and adjusted EBITDA of $105 million to $110 million.
- Q4 2025 GAAP revenue was $116.0 million versus $97.3 million in Q4 2024; full-year 2025 revenue was $441.3 million versus $388.5 million.
- Q4 2025 GAAP net income was $2.4 million, or $0.05 per diluted share, versus a net loss of $16.5 million, or $0.39 per share, in Q4 2024.
- Full-year 2025 adjusted EBITDA was $89.6 million, and the company expects 2026 adjusted EBITDA of $105 million to $110 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.